
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is developing Thermo Acoustic Enhanced UltraSound (TAEUS), aimed at providing a cost-effective diagnostic tool for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) that currently lacks practical solutions. The company's technology is anticipated to receive FDA approval within the next year, which analysts believe could lead to a significant increase in stock value, as reflected in a positive net present value (NPV) analysis indicating considerable upside potential. Furthermore, TAEUS is expected to enhance the diagnosis and monitoring of liver diseases more accurately and cost-effectively than existing methods, creating a strong market demand for its application.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.6 million for the period, equating to an earnings per share (EPS) of $(2.10), which fell short of previously estimated $(1.95). The company's financial outlook is marred by persistent losses and the reiteration of risks associated with balance sheet and liquidity challenges, potential difficulties in demonstrating the safety and efficacy of its products, and uncertainties regarding regulatory approvals. Additionally, the competitive landscape along with shifting investor sentiment in the biotech and medtech sectors poses further risks to the company's ability to commercialize its technology and secure adequate reimbursement, leading to a negative perspective on the stock's future performance.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares